RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Driver, a US-China startup,, which bills itself as “the cure for cancer treatment,” offers to match cancer patients with the best treatment for their particular disease, including clinical trials of novel drugs. After three years in development, the company will start enrolling patients, charging $3000 in a one-time upfront payment and a $20 monthly fee. So far, Driver has raised $90 million, including an investment from Li Ka-shing, the Hong Kong billionaire who founded the Hutchison conglomerate.
Source: China Biotoday
